GlassScriptPhysician profile
Emile Wakim
NPI 1255493136
$1,991.56
in general payments reported to CMS, 2019-2025
18 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $147 · 2021: $100 · 2022: $560 · 2023: $203 · 2024: $185 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $576.85 | 2021-2025 | Tirosint, Licart, Licart |
| Biotissue Holdings INC. | $348.79 | 2022 | |
| Trice Medical, INC. | $256.25 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $157.02 | 2025 | |
| Zimmer Biomet Holdings, INC. | $115.36 | 2019-2024 | Gel-One Cross-Linked Hyaluronate |
| Allergan, INC. | $95.18 | 2019-2022 | |
| Stryker Corporation | $94.26 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $55.68 | 2019-2020 | |
| Depuy Synthes Sales INC. | $47.44 | 2020-2024 | Monovisc |
| Smith+Nephew, INC. | $38.13 | 2019 | |
| Paragon 28, INC. | $37.00 | 2025 | R3flex |
| Micromed INC | $35.56 | 2021 | |
| Abbvie INC. | $27.87 | 2025 | |
| Bioventus LLC | $23.82 | 2025 | Xcell |
| Alk-Abello, INC | $22.72 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.54 | 2021 | |
| Fidia Pharma USA INC. | $19.23 | 2019 | |
| Abbott Laboratories | $18.86 | 2024 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emile Wakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.